Free Trial
NASDAQ:HURA

TuHURA Biosciences (HURA) Stock Price, News & Analysis

TuHURA Biosciences logo
$3.18 -0.03 (-0.93%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$3.20 +0.01 (+0.47%)
As of 05/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TuHURA Biosciences Stock (NASDAQ:HURA)

Key Stats

Today's Range
$3.11
$3.29
50-Day Range
$2.83
$4.23
52-Week Range
$1.80
$7.93
Volume
50,315 shs
Average Volume
241,110 shs
Market Capitalization
$138.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
Consensus Rating
Buy

Company Overview

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Receive HURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HURA Stock News Headlines

Zacks Small Cap Issues Pessimistic Outlook for HURA Earnings
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
Research Analysts Offer Predictions for HURA FY2027 Earnings
What is HC Wainwright's Forecast for HURA FY2025 Earnings?
HURA: First Quarter 2025 Results
See More Headlines

HURA Stock Analysis - Frequently Asked Questions

TuHURA Biosciences' stock was trading at $4.09 at the beginning of 2025. Since then, HURA stock has decreased by 22.2% and is now trading at $3.18.
View the best growth stocks for 2025 here
.

TuHURA Biosciences (NASDAQ:HURA) released its earnings results on Thursday, May, 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02.

Top institutional investors of TuHURA Biosciences include Apollon Wealth Management LLC (0.26%), Suncoast Equity Management (0.23%), Sabal Trust CO (0.09%) and Hurlow Wealth Management Group Inc. (0.07%).

Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/15/2025
Today
5/30/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HURA
Previous Symbol
NASDAQ:HURA
Web
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$15.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+298.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.32 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($4.11) per share
Price / Book
-0.77

Miscellaneous

Free Float
42,200,000
Market Cap
$138.90 million
Optionable
N/A
Beta
0.53
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:HURA) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners